Paul Isaac
Arbiter Partners Capital Management
Paul Isaac Inhibrx Biosciences, Inc stake
total: 298
Arbiter Partners Capital Management INBX trades
- Total transactions:
- 3
- New positions:
- 1
- Sold out:
- 1
- Reduced:
- 1
- Held since:
- 2024 Q3
- Held for:
- 4 quarters
- Latest activity:
- 2025 Q3
According to 2026 Q2 report, Paul Isaac doesn't hold any Inhibrx Biosciences, Inc (INBX) shares. To date, the estimated cost basis is nearly $15.66 for "buy" trades and estimated average "sell" price is $14.27. Arbiter Partners Capital Management first purchased INBX in 2024 Q3, initially acquiring 28,095 shares. Since the initial investment in Inhibrx Biosciences, Inc (INBX), Arbiter Partners Capital Management has made 2 more transactions.
When did Paul Isaac sell Inhibrx Biosciences, Inc (INBX)?
Paul Isaac sold off the entire Inhibrx Biosciences, Inc (INBX) position in 2025 Q3.
When did Paul Isaac buy Inhibrx Biosciences, Inc (INBX)?
Paul Isaac first invested in Inhibrx Biosciences, Inc (INBX) in 2024 Q3 at the reported quarter-end price of $15.66 per share.
What's the cost basis of Arbiter Partners Capital Management's INBX stake?
The estimated cost basis for Inhibrx Biosciences, Inc (INBX) stake is around $15.66 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $15.66
- Weighted AVG sell price:
- $14.27
Paul Isaac's historical trades in Inhibrx Biosciences, Inc
3 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2025 Q3
|
0.00%
|
0
|
$14.27
|
|
-100% (-19,759)
|
-0.25%
|
|
2025 Q2
|
0.25%
|
19,759
|
$14.27
|
$281,960
|
-29.67% (-8,336)
|
-0.14%
|
|
2024 Q3
|
0.87%
|
28,095
|
$15.66
|
$439,967
|
new
|
+0.87%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.